Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

125P - Serum CXCL8 forms a pro-tumor phenotype of circulating neutrophils in clear cell kidney cancer

Date

15 Oct 2022

Session

Poster display session

Presenters

Tatyana Abakumova

Citation

Annals of Oncology (2022) 33 (suppl_8): S1383-S1430. 10.1016/annonc/annonc1095

Authors

T. Abakumova1, I. Myagdieva1, D. Dolgova1, O. Gorshkov2, T. Gening1

Author affiliations

  • 1 Ulyanovsk State University, Ulyanovsk/RU
  • 2 Regional Clinical Oncology Dispensary Ulyanovsk, Ulyanovsk/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 125P

Background

CXCL8 is a neutrophil chemotactic factor (Nph), which is a key effector cell of innate immunity and plays a crucial role in various inflammatory diseases. CXCL8 regulates pathological angiogenesis, tumor growth and metastasis and enhances the protumor effect of Nph (Gonzalez-Aparicio M., 2020). At the same time, protumor Nph (N1) are characterized by reduced expression of chemokines (Sagiv J.Y., 2015). The study was aimed at assessing the expression of the CXCL8 gene by circulating Nph and the serum level of CXCL8 at different stages of clear cell kidney cancer.

Methods

The study included patients with clear cell kidney cancer (KC) stage I (n=30), stage II (n=15), stage III (n=15) (median age 68 years) and 20 healthy patients (control group) (median age 60). The level of CXCL8 (Vector-Best-Volga, Russia) was determined by ELISA in blood serum. RNA isolation was performed from the peripheral blood Nph fraction using SileksMagNA magnetic particles (Sileks, Russia). After isolation, the reverse transcription reaction was set up. Expression of the CXCL8 gene was determined by quantitative PCR with reverse transcription using primers (Evrogen, Russia). Statistical processing was performed using Statistical 13.

Results

We found a significant decrease in CXCL8 gene expression by circulating Nph in patients with stage I KC compared with the control group (5.97±3.15 vs. 117.42±30.89, p=0.01). In the groups of patients at stages II and III, the change in this indicator was statistically insignificant (1.44±0.56, p=0.078 and 36.97±33.05, p=0.226, respectively). No correlation was found between the expression of this gene by Nph and the stage of KC. Serum CXCL8 levels at all stages of KC were higher than those in the control group (78.79±35.41 - KC stage I, p=0.015; 178.79±98.05 - KC stage II, p=0.001; 68.87±23.92 - KC stage III, p=0.0001 versus 12.61±0.87 in the control group). The association of CXCL8 gene expression in Nph with the serum level of this cytokine was found only in stage I kidney cancer (r=0.804, p=0.0016).

Conclusions

In kidney cancer, circulating Nph are not the main producers of serum CXCL8. An elevated level of CXCL8 probably contributes to the formation of a protumor phenotype of circulating Nph.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.